5 Psychiatry Headlines You Missed in April 2026

April 2026 in psychiatry was defined by regulatory expansion, early-stage innovation, and emerging questions around how patients access mental health care. The US Food and Drug Administration (FDA) expanded the label for lumateperone (Caplyta) to include relapse prevention in schizophrenia. A White House executive order accelerated psychedelic research through coordinated action with the FDA and Drug Enforcement Administration (DEA), while clinical trials advanced rapid-acting and mechanism-driven approaches such as GH001. At the same time, increasing reliance on ChatGPT for mental health guidance raised new ethical and clinical oversight concerns for psychiatrists.